AbbVie Inc. is 36.3x more valuable than MADRIGAL PHARMACEUTICALS, INC. by market capitalization ($397.44 B vs $10.94 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MDGL | ABBV |
|---|---|---|
| Market cap | $10.94 B | $397.44 B |
| US-listed rank | #897 | #28 |
| Revenue (latest FY) | $958.40M | $61.16B |
| Net income (latest FY) | -$288.28M | $4.23B |
| Net margin | -30.1% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 1,184 | 1,008 |
AbbVie Inc. is 36.3x more valuable than MADRIGAL PHARMACEUTICALS, INC. by market capitalization ($397.44 B vs $10.94 B).
In their latest fiscal years, MADRIGAL PHARMACEUTICALS, INC. reported $958.40M in revenue while AbbVie Inc. reported $61.16B.
Full pages: MADRIGAL PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.